Strongbridge Biopharma plc (NASDAQ:SBBP) Expected to Announce Earnings of -$0.10 Per Share

Analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to announce ($0.10) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Strongbridge Biopharma’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.11). Strongbridge Biopharma posted earnings per share of ($0.12) during the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The company is scheduled to report its next earnings report on Tuesday, August 3rd.

According to Zacks, analysts expect that Strongbridge Biopharma will report full year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.39). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.09) per share, with EPS estimates ranging from ($0.12) to ($0.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Tuesday, May 11th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). Strongbridge Biopharma had a negative return on equity of 72.48% and a negative net margin of 136.23%. The company had revenue of $8.38 million for the quarter, compared to analyst estimates of $8.22 million.

A number of research firms have recently weighed in on SBBP. JMP Securities downgraded shares of Strongbridge Biopharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 25th. Craig Hallum downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating and dropped their price target for the company from $9.00 to $3.25 in a research report on Tuesday, May 25th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Strongbridge Biopharma currently has a consensus rating of “Hold” and an average target price of $5.31.

Shares of NASDAQ SBBP traded down $0.05 during midday trading on Thursday, reaching $2.73. The company’s stock had a trading volume of 30,277 shares, compared to its average volume of 791,414. The company has a current ratio of 3.63, a quick ratio of 3.58 and a debt-to-equity ratio of 0.31. Strongbridge Biopharma has a fifty-two week low of $1.87 and a fifty-two week high of $4.40. The stock’s 50 day moving average price is $2.77.

A number of large investors have recently made changes to their positions in SBBP. BlackRock Inc. grew its stake in shares of Strongbridge Biopharma by 10.5% during the fourth quarter. BlackRock Inc. now owns 2,111,625 shares of the biotechnology company’s stock worth $5,131,000 after buying an additional 201,125 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Strongbridge Biopharma by 82.1% during the fourth quarter. Bank of New York Mellon Corp now owns 155,882 shares of the biotechnology company’s stock worth $379,000 after buying an additional 70,297 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Strongbridge Biopharma by 36.9% during the fourth quarter. Wells Fargo & Company MN now owns 195,178 shares of the biotechnology company’s stock worth $475,000 after buying an additional 52,610 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Strongbridge Biopharma by 39.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,189,200 shares of the biotechnology company’s stock worth $5,320,000 after buying an additional 620,011 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Strongbridge Biopharma by 18.3% during the fourth quarter. Rhumbline Advisers now owns 29,736 shares of the biotechnology company’s stock worth $72,000 after buying an additional 4,595 shares during the last quarter. 50.62% of the stock is currently owned by institutional investors and hedge funds.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.

Featured Article: Terms to Better Understand Call Options

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.